Ikonisys

🚀 Exciting News from Ikonisys! 🚀 We are thrilled to announce the launch of our latest innovation, the Ikoniscope Max, at the 36th European Congress of Pathology in Florence! The #IkoniscopeMax is a cutting-edge automated digital microscope designed to meet the growing demands of high-productivity laboratories. With its unmatched precision, speed, and automation, it is set to revolutionize digital pathology and empower pathologists with faster and more accurate diagnoses. 🧬🔬 This launch marks a significant milestone in our commitment to advancing the field of pathology, and we are excited to showcase this groundbreaking technology alongside Europe’s leading pathologists. Attendees at launch event will have the exclusive opportunity to experience the Ikoniscope Max in action and explore its transformative capabilities. For more information, visit ikonisys-finance.com. #Ikonisys #PathologyInnovation #FISH #EuropeanCongressOfPathology #Ikoniscope #Hospitex

We are proud to present our #Iconiscope MAX at such an exclusive event in Florence.

Ikonisys, società quotata a Parigi e specializzata nella rilevazione precoce e accurata dei tumori, e Ulisse BioMed, healthcare biotech company quotata a Piazza Affari, hanno stretto una partnership strategica nell'ambito della diagnostica oncologica. 📩La notizia: https://lnkd.in/eMc7QZNf

Proud to be part of this beautiful cooperative initiative to make oncology diagnostics more efficient.

Hospitex International Srl, member of the #Ikonisys Group, has signed a new distribution partnership in Ukraine with #Diagen LLC, a leading Ukrainian distributor and laboratory services provider. This collaboration aims at reinforcing the Company’s commitment to the global fight against cancer. Despite the challenging environment amidst the war, this strategic alliance represents a significant step in Hospitex’s mission to enhance the accessibility of advanced cancer diagnostic tools and treatments and make innovative healthcare solutions available to those who need them most. The market for cytology in Ukraine is substantial with a growing emphasis on early cancer detection and preventive healthcare. #UrinaryCytology is also becoming more significant, with thousands of tests performed each year to diagnose and monitor urinary tract cancers. By introducing Hospitex's advanced diagnostic products into this market, the aim is to significantly enhance the accuracy and efficiency of critical tests.   In the framework of this partnership, Diagen LLC will both distribute Hospitex's cutting-edge technologies and use them in its own laboratory, particularly for Pap smear tests and urinary cytology. Thanks to Hospitex’s expertise, Diagen LLC will enable Ukrainian healthcare professionals to have access to reliable and precise diagnostic tools. “Partnering with Diagen LLC in Ukraine during such tumultuous times is a testament to our dedication to the global fight against cancer and its spread worldwide”, said Francesco Trisolini, CEO of Hospitex. “We believe that every patient, regardless of their circumstances, deserves the best possible care. This initiative once again demonstrates our commitment to supporting healthcare systems and providing crucial medical supplies where they are most needed. Our new distributor and partner, Diagen LLC, shares our vision and commitment to improving healthcare outcomes. Together, we will focus on ensuring that even amidst adversity, the fight against cancer continues unabated.”   The first delivery to Diagen LLC has recently been recorded contributing to H1 2024 Hospitex’s revenue. The next phase of this collaboration consists into introducing Ikonisys’ products into the Ukrainian market, further enhancing diagnostic capabilities and patient care. Mario Crovetto, CEO of Ikonisys, declares: “We are thrilled to announce this new milestone as our ambition to contribute to the fight against cancer globally is very high. We look forward to providing active support to this territory in the midst of conflict and improve the lives of the population in need there.” This collaboration is part of Hospitex’s and Ikonisys’ broader strategy to expand their global footprint and provide essential medical technology to underserved regions. By enhancing their distribution network, the Companies are taking proactive steps to address the global burden of cancer, delivering hope and improved health outcomes to communities in need.

#BladderCancer is the ninth most frequent neoplasm in the world and the most frequent of the genito-urinary tract. The most recognized risk factors for carcinoma are cigarette smoking, advanced age, and occupational exposure to paints and solvents. Screening can be done with noninvasive investigations such as hematuria detection and #UrinaryCytology. In most cases, the diagnostic process starts with the chance finding of traces of blood in urine and the subsequent finding of atypical cells in urine collected at three different times (cytological examination). The next step is an exploratory cystoscopy, which, in the most favourable scenario, allows the tumor to be visually identified and fragments (biopsies) taken for histological diagnosis. Once diagnosed, most often the tumor can be excised endoscopically through an operative cystoscopy under general or peridural anaesthesia. However, it should be mentioned that cytological examination is falsely negative in 50% of cases and exploratory cystoscopy is falsely negative in 30% of cases. Coupling cytologic examination to exploratory cystoscopy therefore fails to ensure 100 percent diagnostic sensitivity, with the risk of exhausting (for the patient) and costly (for the SSR) diagnostic sequelae (repeated cystoscopies, CT, NMR, ultrasound). Urothelial cell carcinoma is characterized by the increase of chromosomes 3, 7 and 17 and the loss of the gene at position 9p21 (which codes for the oncosuppressor p16). Using the #FISH (Fluorescence In Site Hybridization) technique, it is possible to count chromosomes 3,7 and 17 and copies of the 9p21 gene in urine-emitted cells. The #FISHtechnique, when coupled with automatic analysis of results, achieves 99% sensitivity. Our #Ikoniscope’s FISH technology makes it possible to quantify the percentage of pathological cells, and this is of great clinical importance since it has now been scientifically demonstrated that this percentage is directly proportional to the invasiveness of the tumor. Therefore, in cases of sure positivity on FISH, an exploratory cystoscopy can be avoided and instead a CT scan can be used to localize the tumor before operative cystoscopy; conversely, in cases of definitely negative FISH, an exploratory follow-up cystoscopy can be procrastinated. All this translates into greater clinical effectiveness (better diagnostic sensitivity, less invasiveness, less time, less cost).

Proud to share such a big collaboration in cancer diagnostics. Together with #Hospitex we're pioneering advancements in cancer diagnostics, harnessing the power of cutting-edge technology to enhance detection accuracy and efficiency.

𝐂𝐢𝐫𝐜𝐮𝐥𝐚𝐭𝐢𝐧𝐠 𝐓𝐮𝐦𝐨𝐫 𝐂𝐞𝐥𝐥𝐬 𝐌𝐚𝐫𝐤𝐞𝐭: 𝐏𝐢𝐨𝐧𝐞𝐞𝐫𝐢𝐧𝐠 𝐃𝐞𝐭𝐞𝐜𝐭𝐢𝐨𝐧 𝐚𝐧𝐝 𝐌𝐨𝐧𝐢𝐭𝐨𝐫𝐢𝐧𝐠 𝐢𝐧 𝐂𝐚𝐧𝐜𝐞𝐫 𝐂𝐚𝐫𝐞 𝐆𝐞𝐭 𝐒𝐚𝐦𝐩𝐥𝐞 𝐏𝐃𝐅 @ https://lnkd.in/d6z7CJGR The market size of the Circulating Tumor Cells was approximated at USD 10.4 billion in 2022, projected to attain USD 28.4 billion by 2030, with a compelling compound annual growth rate (CAGR) of 13.4% during the forecast period spanning 2023 to 2030. In the dynamic landscape of oncology, the Circulating Tumor Cells (CTCs) market emerges as a pivotal player, revolutionizing the way cancer is detected, monitored, and treated. These minuscule cells, shed from primary tumors into the bloodstream, offer unprecedented insights into the progression and dynamics of cancer. With advancements in technology and diagnostic methods, the CTCs market is witnessing exponential growth, driven by the demand for non-invasive, real-time monitoring solutions. This burgeoning market not only facilitates early detection but also enables clinicians to tailor personalized treatment regimens, ultimately enhancing patient outcomes and revolutionizing the paradigm of cancer management. 𝐓𝐡𝐞 𝐌𝐚𝐣𝐨𝐫 𝐊𝐞𝐲 𝐏𝐥𝐚𝐲𝐞𝐫𝐬 →QIAGEN, →Bio-Techne, →Thermo Fisher Scientific, →Precision For Medicine, →AVIVA Biosciences, →Biocept, Inc. , →Fluxion Biosciences, →Greiner Bio-One International , →Ikonisys., →Miltenyi Biotec,  →Menarini Silicon Biosystems, →LineaRx, Inc. (Vitatex, Inc.), →STEMCELL Technologies, Inc.,  →and Others. #QIAGEN #BioTechneCorporation #ThermoFisherScientific #PrecisionforMedicine #AVIVABiosciences #BIOCEPT #FluxionBiosciences #GreinerBioOneInternational #IkonisysInc #MiltenyiBiotec #MenariniSiliconBiosystems #LineaRx #STEMCELLTechnologies #CirculatingTumorCells #CTCMarket #CancerDetection #PrecisionMedicine #Biotechnology #MedicalResearch #HealthcareInnovation #Biosciences #CirculatingTumorCells #CTCMarket #CancerDetection #LiquidBiopsy #PrecisionOncology #CancerResearch #TumorBiomarkers #LiquidBiopsyTechnology #CancerMonitoring #BiomarkerDiscovery #OncologyResearch #NonInvasiveTesting #PersonalizedMedicine #CancerScreening #DiagnosticInnovation #HealthcareAdvancements #MedicalTechnology

#ikonisys, a company specializing in the early and accurate diagnosis of cancer through a unique and fully automated solution for medical testing laboratories, is pleased to announce the installation of the #Ikoniscope at Hospitex Lab. Hospitex Lab is the pathology anatomy laboratory located at the #hospitexinternational headquarters. This integration provides an ideal platform for the business operations of #IkonisysEurope, which will use the laboratory as a showroom, demonstration point, training center and center of excellence for #FISHtechnology. To this end, a series of promotional initiatives are planned with the participation of leading representatives of the medical and scientific community, first in Italy and then at the European level. Ikonoscope’s FISH technology will also be used internally by integrating it into #Urine24, Hospitex’s consumer oncology diagnostic product, further improving its sensitivity, reliability and efficiency. Finally, an offer to provide FISH technology as-a-service is being studied, targeting small private and public centers that do not have sufficient staff to handle a full installation, thus representing an additional source of revenue for the Group in the medium term. Mario Crovetto, CEO of Ikonisys, and Francesco Trisolini, CEO of Hospitex International, comment: "Early developments indicate that the integration of the two companies, which announced their merger plans in early December, is progressing at a record pace. These developments also underscore the significance of this transaction, as it aims to create substantial operational and business synergies."